Comparative effectiveness of therapies for graves' hyperthyroidism

A systematic review and network meta-A nalysis

Vishnu Sundaresh, Juan Brito Campana, Zhen Wang, Larry J. Prokop, Marius N. Stan, Mohammad H Murad, Rebecca S. Bahn

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

Context: Several treatment options are available for Graves' disease (GD), including antithyroid drugs (ATDs), radioactive iodine (RAI), and thyroidectomy. Objective: The primary outcome was to determine the relapse rates of various treatment options. The secondary outcome was to present data regarding adverse effects of ATDs. Data Sources: We searched multiple databases through March 2012. Study Selection: Eligible studies were randomized clinical trials and comparative cohort studies in adults that included 2 or more treatment options for GD. Data Extraction: Two reviewers independently selected studies, appraised study quality, extracted outcome data, and determined adverse effect profiles. Data Synthesis: We found 8 studies with 1402 patients from 5 continents. Mean follow-up duration inmonthswas:ATDs,57; RAI, 64;andsurgery, 59. Studieswereatmoderatetohighriskofbias.Network meta-A nalysis suggested higher relapse rates with ATDs (52.7%; 352 of 667) than RAI (15%, 46 of 304) (odds ratio6.25; 95% confidence interval, 2.40-16.67) and with ATDs than surgery (10%; 39 of 387) (odds ratio9.09;95%confidence interval, 4.65-19.23). There was no significant difference in relapse between RAI and surgery. Examination of 31 cohort studies identified adverse effects of ATDs in 692 of 5136 (13%) patients. Theseweremorecommonwith methimazole, mainlyowingto dermatological complications, whereas hepatic effects were more common with propylthiouracil use. Conclusion: We confirm the relatively high relapse rate of ATD therapy in comparison with RAI or surgery, along with a significant side effect profile for these drugs. These data can inform discussion between physicians and patients regarding the choice of therapy for GD. The limited quality of the evidence in the literature underlines the need for future randomized clinical trials in this area.

Original languageEnglish (US)
Pages (from-to)3671-3677
Number of pages7
JournalJournal of Clinical Endocrinology and Metabolism
Volume98
Issue number9
DOIs
StatePublished - Sep 2013

Fingerprint

Antithyroid Agents
Hyperthyroidism
Iodine
Graves Disease
Surgery
Recurrence
Therapeutics
Cohort Studies
Randomized Controlled Trials
Confidence Intervals
Methimazole
Drug therapy
Propylthiouracil
Information Storage and Retrieval
Thyroidectomy
Drug-Related Side Effects and Adverse Reactions
Databases
Physicians
Drug Therapy
Liver

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Endocrinology
  • Biochemistry, medical
  • Endocrinology, Diabetes and Metabolism

Cite this

Comparative effectiveness of therapies for graves' hyperthyroidism : A systematic review and network meta-A nalysis. / Sundaresh, Vishnu; Brito Campana, Juan; Wang, Zhen; Prokop, Larry J.; Stan, Marius N.; Murad, Mohammad H; Bahn, Rebecca S.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 98, No. 9, 09.2013, p. 3671-3677.

Research output: Contribution to journalArticle

@article{9b8e8e23d620446593d2338dd6eb4c3e,
title = "Comparative effectiveness of therapies for graves' hyperthyroidism: A systematic review and network meta-A nalysis",
abstract = "Context: Several treatment options are available for Graves' disease (GD), including antithyroid drugs (ATDs), radioactive iodine (RAI), and thyroidectomy. Objective: The primary outcome was to determine the relapse rates of various treatment options. The secondary outcome was to present data regarding adverse effects of ATDs. Data Sources: We searched multiple databases through March 2012. Study Selection: Eligible studies were randomized clinical trials and comparative cohort studies in adults that included 2 or more treatment options for GD. Data Extraction: Two reviewers independently selected studies, appraised study quality, extracted outcome data, and determined adverse effect profiles. Data Synthesis: We found 8 studies with 1402 patients from 5 continents. Mean follow-up duration inmonthswas:ATDs,57; RAI, 64;andsurgery, 59. Studieswereatmoderatetohighriskofbias.Network meta-A nalysis suggested higher relapse rates with ATDs (52.7{\%}; 352 of 667) than RAI (15{\%}, 46 of 304) (odds ratio6.25; 95{\%} confidence interval, 2.40-16.67) and with ATDs than surgery (10{\%}; 39 of 387) (odds ratio9.09;95{\%}confidence interval, 4.65-19.23). There was no significant difference in relapse between RAI and surgery. Examination of 31 cohort studies identified adverse effects of ATDs in 692 of 5136 (13{\%}) patients. Theseweremorecommonwith methimazole, mainlyowingto dermatological complications, whereas hepatic effects were more common with propylthiouracil use. Conclusion: We confirm the relatively high relapse rate of ATD therapy in comparison with RAI or surgery, along with a significant side effect profile for these drugs. These data can inform discussion between physicians and patients regarding the choice of therapy for GD. The limited quality of the evidence in the literature underlines the need for future randomized clinical trials in this area.",
author = "Vishnu Sundaresh and {Brito Campana}, Juan and Zhen Wang and Prokop, {Larry J.} and Stan, {Marius N.} and Murad, {Mohammad H} and Bahn, {Rebecca S.}",
year = "2013",
month = "9",
doi = "10.1210/jc.2013-1954",
language = "English (US)",
volume = "98",
pages = "3671--3677",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "9",

}

TY - JOUR

T1 - Comparative effectiveness of therapies for graves' hyperthyroidism

T2 - A systematic review and network meta-A nalysis

AU - Sundaresh, Vishnu

AU - Brito Campana, Juan

AU - Wang, Zhen

AU - Prokop, Larry J.

AU - Stan, Marius N.

AU - Murad, Mohammad H

AU - Bahn, Rebecca S.

PY - 2013/9

Y1 - 2013/9

N2 - Context: Several treatment options are available for Graves' disease (GD), including antithyroid drugs (ATDs), radioactive iodine (RAI), and thyroidectomy. Objective: The primary outcome was to determine the relapse rates of various treatment options. The secondary outcome was to present data regarding adverse effects of ATDs. Data Sources: We searched multiple databases through March 2012. Study Selection: Eligible studies were randomized clinical trials and comparative cohort studies in adults that included 2 or more treatment options for GD. Data Extraction: Two reviewers independently selected studies, appraised study quality, extracted outcome data, and determined adverse effect profiles. Data Synthesis: We found 8 studies with 1402 patients from 5 continents. Mean follow-up duration inmonthswas:ATDs,57; RAI, 64;andsurgery, 59. Studieswereatmoderatetohighriskofbias.Network meta-A nalysis suggested higher relapse rates with ATDs (52.7%; 352 of 667) than RAI (15%, 46 of 304) (odds ratio6.25; 95% confidence interval, 2.40-16.67) and with ATDs than surgery (10%; 39 of 387) (odds ratio9.09;95%confidence interval, 4.65-19.23). There was no significant difference in relapse between RAI and surgery. Examination of 31 cohort studies identified adverse effects of ATDs in 692 of 5136 (13%) patients. Theseweremorecommonwith methimazole, mainlyowingto dermatological complications, whereas hepatic effects were more common with propylthiouracil use. Conclusion: We confirm the relatively high relapse rate of ATD therapy in comparison with RAI or surgery, along with a significant side effect profile for these drugs. These data can inform discussion between physicians and patients regarding the choice of therapy for GD. The limited quality of the evidence in the literature underlines the need for future randomized clinical trials in this area.

AB - Context: Several treatment options are available for Graves' disease (GD), including antithyroid drugs (ATDs), radioactive iodine (RAI), and thyroidectomy. Objective: The primary outcome was to determine the relapse rates of various treatment options. The secondary outcome was to present data regarding adverse effects of ATDs. Data Sources: We searched multiple databases through March 2012. Study Selection: Eligible studies were randomized clinical trials and comparative cohort studies in adults that included 2 or more treatment options for GD. Data Extraction: Two reviewers independently selected studies, appraised study quality, extracted outcome data, and determined adverse effect profiles. Data Synthesis: We found 8 studies with 1402 patients from 5 continents. Mean follow-up duration inmonthswas:ATDs,57; RAI, 64;andsurgery, 59. Studieswereatmoderatetohighriskofbias.Network meta-A nalysis suggested higher relapse rates with ATDs (52.7%; 352 of 667) than RAI (15%, 46 of 304) (odds ratio6.25; 95% confidence interval, 2.40-16.67) and with ATDs than surgery (10%; 39 of 387) (odds ratio9.09;95%confidence interval, 4.65-19.23). There was no significant difference in relapse between RAI and surgery. Examination of 31 cohort studies identified adverse effects of ATDs in 692 of 5136 (13%) patients. Theseweremorecommonwith methimazole, mainlyowingto dermatological complications, whereas hepatic effects were more common with propylthiouracil use. Conclusion: We confirm the relatively high relapse rate of ATD therapy in comparison with RAI or surgery, along with a significant side effect profile for these drugs. These data can inform discussion between physicians and patients regarding the choice of therapy for GD. The limited quality of the evidence in the literature underlines the need for future randomized clinical trials in this area.

UR - http://www.scopus.com/inward/record.url?scp=84883691461&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883691461&partnerID=8YFLogxK

U2 - 10.1210/jc.2013-1954

DO - 10.1210/jc.2013-1954

M3 - Article

VL - 98

SP - 3671

EP - 3677

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 9

ER -